A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine

Inclusion Criteria Patients may be eligible for this study if they: * Have a viral load of 2,000 or more copies/ml and a CD4 cell count of 100 or more cells/mm3 (or 75 or more cells/mm3 with no prior history of AIDS-defining diagnosis) within 2 weeks before randomization. * Are at least 16 years old. * Have signed consent of parent or guardian if under 18 years of age. * Are willing to use effective barrier methods of birth control. * Are available for follow-up for at least 52 weeks. Exclusion Criteria Patients will not be eligible for this study if they: * Have had anti-HIV treatment within 30 days before screening. * Have a recently diagnosed HIV-related infection. * Have any medical condition requiring treatment at enrollment. * Have recently become HIV infected. * Have acute hepatitis within 30 days of study entry. Certain patients with chronic hepatitis will be eligible. * Expect to need or have taken drugs with myelosuppressive, neurotoxic, pancreatotoxic, hepatotoxic, or cytotoxic potential within 3 months before study. Expect to need methadone, ribavirin/interferons, neurotoxic drugs or drugs that affect CYP3A4. * Abuse alcohol or drugs. * Have severe diarrhea within 30 days before study entry. * Are pregnant or breast-feeding. * Have a history of hemophilia. * Have a history of bilateral peripheral neuropathy. * Cannot take medicines by mouth. * Have any other conditions that the doctor thinks would interfere with the study.